Journal of Biological Chemistry · 1998 · 62 citations · 39 references
Life SciencesMolecular BiologyPhysiologyCell SignalingImmunoregulationSignal TransductionG Protein-coupled Receptor SignalingReceptor PhysiologyReceptor RegulationCamp SignalingCdna CloningConstitutive Receptor ActivityExtracellular DomainsG Protein-coupled Neuropeptide ReceptorsG Protein-coupled Receptor ActivationG-protein-coupled ReceptorsVasoactive Intestinal Peptide Signaling
The human vasoactive intestinal peptide (VIP) 1 receptor belongs to the new class II subfamily of G protein-coupled receptors. Specific change by mutagenesis of a strictly conserved histidine into arginine at position 178 of the human VIP1 receptor resulted in its constitutive activation with respect to cAMP production. Transfection of the H178R mutant into COS cells resulted in a 3.5-fold increase in the cAMP level as compared with cells transfected with the wild type receptor or the vector alone. This increase was proportional to the amount of transfected cDNA. The H178R mutant exhibited an otherwise normal cAMP response to VIP as well as a dissociation constant similar to that of the wild type receptor. Other mutants at position 178 such as H178K, H178A, and H178D were not constitutively activated. They were otherwise expressed at the cell surface of transfected nonpermeabilized cells. Double mutants were then constructed in which the H178R mutation was associated with a point mutation in the the N-terminal extracellular domain that totally abolished VIP binding or VIP-stimulated cAMP production,i.e. E36A or D68A. The corresponding double mutants H178R/E36A and H178R/D68A were no longer constitutively activated. A control double mutant (H178R/D132A) with an unaltered dissociation constant for VIP and cAMP response to VIP was still constitutively activated. Our findings demonstrate that constitutive activation of the VIP1 receptor by mutation of His178 into R requires the functional integrity of the N-terminal extracellular VIP binding domain. They might provide interesting generalities about the activation process of G protein-coupled receptors. The human vasoactive intestinal peptide (VIP) 1 receptor belongs to the new class II subfamily of G protein-coupled receptors. Specific change by mutagenesis of a strictly conserved histidine into arginine at position 178 of the human VIP1 receptor resulted in its constitutive activation with respect to cAMP production. Transfection of the H178R mutant into COS cells resulted in a 3.5-fold increase in the cAMP level as compared with cells transfected with the wild type receptor or the vector alone. This increase was proportional to the amount of transfected cDNA. The H178R mutant exhibited an otherwise normal cAMP response to VIP as well as a dissociation constant similar to that of the wild type receptor. Other mutants at position 178 such as H178K, H178A, and H178D were not constitutively activated. They were otherwise expressed at the cell surface of transfected nonpermeabilized cells. Double mutants were then constructed in which the H178R mutation was associated with a point mutation in the the N-terminal extracellular domain that totally abolished VIP binding or VIP-stimulated cAMP production,i.e. E36A or D68A. The corresponding double mutants H178R/E36A and H178R/D68A were no longer constitutively activated. A control double mutant (H178R/D132A) with an unaltered dissociation constant for VIP and cAMP response to VIP was still constitutively activated. Our findings demonstrate that constitutive activation of the VIP1 receptor by mutation of His178 into R requires the functional integrity of the N-terminal extracellular VIP binding domain. They might provide interesting generalities about the activation process of G protein-coupled receptors. G protein-coupled receptors with seven transmembrane domains, which constitute a large multigene family of eucaryotic proteins, interact with alkaloids, biogenic amines, peptides, glycoprotein hormones, light, and odorants (1Van Rhee A.V. Jacobson K.A. Drug Develop. Res. 1996; 37: 1-38Google Scholar). During the past few years, a subfamily of the superfamily of G protein-coupled receptors has emerged that shares the seven-membrane-spanning domain topography but has a low overall amino acid sequence homology (<20%) with other members of the superfamily (2Segre G.V. Goldring S.R. Trends Endocrinol. Metab. 1993; 4: 309-314Google Scholar, 3Laburthe M. Couvineau A. Gaudin P. Maoret J.J. Rouyer-Fessard C. Nicole P Ann. N. Y. Acad. Sci. 1996; 805: 94-109Google Scholar). This subfamily, now referred to as the class II G protein-coupled receptor family, comprises receptors for a family of structurally related peptides that includes vasoactive intestinal peptide (VIP), 1The abbreviations used are: VIP, vasoactive intestinal peptide; PTH, parathyroid hormone; EMR1, epidermal growth factor module-containing, mucin-like hormone receptor; PBS, phosphate-buffered saline; CHO, Chinese hamster ovary; FITC, fluorescein isothiocyanate; PTHrP, parathyroid hormone-related peptide. pituitary adenylate cyclase-activating polypeptide, glucagon, secretin, glucagon-like peptide 1, gastric inhibitory polypeptide, and growth hormone-releasing peptide and more unexpectedly also comprises receptors for parathyroid hormone (PTH) and calcitonin (2Segre G.V. Goldring S.R. Trends Endocrinol. Metab. 1993; 4: 309-314Google Scholar, 3Laburthe M. Couvineau A. Gaudin P. Maoret J.J. Rouyer-Fessard C. Nicole P Ann. N. Y. Acad. Sci. 1996; 805: 94-109Google Scholar, 4Birnbaumer M. J. Recept. Signal Transduct. Res. 1995; 15: 131-160Google Scholar). Recent studies have extended this subfamily (3Laburthe M. Couvineau A. Gaudin P. Maoret J.J. Rouyer-Fessard C. Nicole P Ann. N. Y. Acad. Sci. 1996; 805: 94-109Google Scholar) with the discovery of subtypes of the above mentioned receptors as well as two new members having an extraordinary long N-terminal domain: the putative EGF module-containing, mucin-like hormone receptor EMR1 (5Baud V. Chissoe S.L. Viegas-Pequignot E. Diriong S. N'Guyen V.C. Roe B.A. Lipinski M. Genomics. 1995; 6: 334-344Google Scholar) and the leukocyte activation antigen CD97 (6Hamman J. Eichler W. Hamman D. Kersten H.M.J. Poddhige P.J. Hoovers J.M.N. Hartmann E. Strauss M. Van Vlier R.A.W. J. Immunol. 1995; 155: 1942-1950Google Scholar). Class II G protein-coupled receptors for peptides have homologies ranging between 30 and 50% and among several common structural properties have a large N-terminal extracellular domain (>120 amino acid residues) that contains highly conserved amino acids, including numerous cysteine residues and several potential N-linked glycosylation sites (2Segre G.V. Goldring S.R. Trends Endocrinol. Metab. 1993; 4: 309-314Google Scholar, 3Laburthe M. Couvineau A. Gaudin P. Maoret J.J. Rouyer-Fessard C. Nicole P Ann. N. Y. Acad. Sci. 1996; 805: 94-109Google Scholar). Taking the human VIP1 receptor (7Couvineau A. Rouyer-Fessard C. Darmoul D. Maoret J.J. Carrero I. Ogier-Denis E. Laburthe M. Biochem. Biophys. Res. Commun. 1994; 200: 769-776Google Scholar), which activates adenylyl cyclase via stimulatory Gs proteins (8Couvineau A. Amiranoff B. Laburthe M. J. Biol. Chem. 1986; 261: 14482-14489Google Scholar), as a prototype of class II G protein-coupled receptors, we recently provided evidence for an important role of the N-terminal domain for ligand binding with several crucial residues (9Couvineau A. Gaudin P. Maoret J.J. Rouyer-Fessard C. Nicole P. Laburthe M. Biochem. Biophys. Res. Commun. 1995; 206: 246-252Google Scholar) probably positioned in a tertiary structure maintained by multiple disulfide bonds (10Gaudin P. Couvineau A. Maoret J.J. Rouyer-Fessard C. Laburthe M. Biochem. Biophys. Res. Commun. 1995; 211: 901-908Google Scholar). We also demonstrated the mandatory role of two glycosylation sites in this domain for correct delivery of the receptor to the plasma membrane (11Couvineau A. Fabre C. Gaudin P. Maoret J.J. Laburthe M. Biochemistry. 1996; 35: 1745-1752Google Scholar). Other functional domains for ligand recognition do exist, since we showed, by constructing receptor chimeras, that a structural determinant for peptide selectivity was made of three nonadjacent amino acid residues in the first extracellular loop and third transmembrane domain (12Couvineau A. Rouyer-Fessard C. Maoret J.-J. Gaudin P. Nicole P. Laburthe M. J. Biol. Chem. 1996; 271: 12795-12800Google Scholar). The role of extracellular domains in natural ligand binding has now been documented for several members of class II G protein-coupled receptors such as rat VIP1 and secretin (13Holtmann M.H. Hadac E.M. Miller L.J. J. Biol. Chem. 1995; 270: 14394-14398Google Scholar, 14Vilardaga J.P. De Neef P. Di Paolo E. Bollen A. Waelbroeck M. Robberecht P. Biochem. Biophys. Res. Commun. 1995; 211: 885-891Google Scholar), pituitary adenylate cyclase-activating polypeptide (15Cao Y.J. Gimpl G. Fahrenholz F. Biochem. Biophys. Res. Commun. 1995; 212: 673-680Google Scholar), calcitonin (16Houssami S. Findlay D.M. Brady C.L. Myers D.E. Martin T.J. Sexton P.M. Endocrinology. 1994; 135: 183-190Google Scholar), PTH (17Jüppner H. Schipani E. Bringhurst F.R. McClure I. Keutmann H.T. Potts Jr., J.T. Kronenberg H.M. Abou-Smara A.B. Segre G.V. Gardella T.J. Endocrinology. 1994; 134: 879-884Google Scholar, 18Lee C. Gardella T.J. Abou-Smara A.B. Nussbaum S.R. Segre G.V. Potts Jr., J.T. Kronenberg H.M. Jüppner H. Endocrinology. 1994; 135: 1488-1495Google Scholar), glucagon (19Hager J. Hansen L. Vaisse C. Vionnet N. Philippi A. Poller W. Vehlo G. Carcassi C. Contu L. Julier C. Cambien F. Passa P. Lathrop M. Kindsvogel W. Demenais F. Nishimura E. Froguel P. Nat. Genet. 1995; 9: 299-304Google Scholar, 20Unson C.G. Cypess A.M. Wu C.R. Goldsmith P.K. Merrifield Acad. Sci. S. A. 1996; Scholar), glucagon-like peptide 1 A. B. 1996; P.J. 1996; 4: Scholar), or growth hormone-releasing peptide C.R. I. 1993; Scholar) receptors. mutants of several G protein-coupled receptors have been by mutagenesis S. P. Trends Sci. 1993; Scholar) and have been also as in J. L. Van J. M. J. G. Endocrinol. 1994; A.M. 1995; Scholar). A constitutively mutant of a class II G receptor has been for the peptide receptor in a strictly conserved histidine in the first loop of this class of receptor E. H. 1995; Scholar). of the that class II G protein-coupled receptors an with respect to ligand recognition and low sequence homology with other G protein-coupled receptors (2Segre G.V. Goldring S.R. Trends Endocrinol. Metab. 1993; 4: 309-314Google Scholar, 3Laburthe M. Couvineau A. Gaudin P. Maoret J.J. Rouyer-Fessard C. Nicole P Ann. N. Y. Acad. Sci. 1996; 805: 94-109Google Scholar), we constitutive activation in the human VIP1 receptor has been documented (3Laburthe M. Couvineau A. Gaudin P. Maoret J.J. Rouyer-Fessard C. Nicole P Ann. N. Y. Acad. Sci. 1996; 805: 94-109Google Scholar). this we demonstrate that mutation of histidine 178 in the VIP receptor its constitutive we of the that the VIP binding at in in the N-terminal extracellular domain to double mutants in which the mutation for constitutive activation has been associated with point in the N-terminal domain that VIP This new to that the constitutive activation of the mutant to the integrity of the natural ligand binding provide new into the constitutive activation of G protein-coupled receptors. for and mutagenesis were or and were and other were VIP was and and was and as M. M. Rouyer-Fessard C. Couvineau A. I. G. A. J. Biol. Chem. Scholar). The were and was other of the were The the sequence of the human VIP1 receptor (7Couvineau A. Rouyer-Fessard C. Darmoul D. Maoret J.J. Carrero I. Ogier-Denis E. Laburthe M. Biochem. Biophys. Res. Commun. 1994; 200: 769-776Google Scholar) was into the of the and was in VIP receptor mutants were by mutagenesis as (11Couvineau A. Fabre C. Gaudin P. Maoret J.J. Laburthe M. Biochemistry. 1996; 35: 1745-1752Google Scholar). of the was by of the mutant were in the vector The wild type and mutant receptors were in the N-terminal extracellular domain by the between and The sequence was by mutagenesis as above This of was between the of the putative peptide (3Laburthe M. Couvineau A. Gaudin P. Maoret J.J. Rouyer-Fessard C. Nicole P Ann. N. Y. Acad. Sci. 1996; 805: 94-109Google Scholar, A. Rouyer-Fessard C. Darmoul D. Maoret J.J. Carrero I. Ogier-Denis E. Laburthe M. Biochem. Biophys. Res. Commun. 1994; 200: 769-776Google Scholar) and which has been to the first crucial amino acid for human VIP1 functional properties P. Couvineau A. Laburthe M. 1996; Scholar). was that of the sequence between and not the dissociation constant for VIP or the response of VIP in cAMP as compared with the human VIP1 receptor. type and mutant VIP receptors were transfected into cells or cells. were in for or for with in a of and at were transfected by the an II cells were in for with of used as and of wild type or mutant receptor in phosphate-buffered for cells or for cells were for and then into and in for binding for the cAMP or for binding or in for The was and cells were used The functional properties of wild type and mutant VIP receptors were by binding to transfected cell cells were with phosphate-buffered were with a and at for at and the cell were for 30 in a cells were as M. M. Rouyer-Fessard C. Couvineau A. I. G. A. J. Biol. Chem. Scholar), and the was at for at The was with and at This was referred to as the membrane of were for at 30 in in the of of The was as M. M. Rouyer-Fessard C. Couvineau A. I. G. A. J. Biol. Chem. Scholar). Specific binding was as the between the amount in the and the of 1 were the P.J. D. Biochem. Scholar). in membrane was by the of Biochem. Scholar) with as cells or cells were in as The was and cells were with phosphate-buffered They were then with or VIP in of phosphate-buffered and 1 as (7Couvineau A. Rouyer-Fessard C. Darmoul D. Maoret J.J. Carrero I. Ogier-Denis E. Laburthe M. Biochem. Biophys. Res. Commun. 1994; 200: 769-776Google Scholar). the of the at the was and cells were by 1 The cAMP in the was by as M. M. C. G. A. G. Acad. Sci. S. A. Scholar). was in and as of cells. cells were for as were with phosphate-buffered nonpermeabilized cells were for at with the in The cells were then three with and for to the at a were then for in The were in 50% in PBS, and were a of a with an with an of and a to an for The was a long the of the was with a to increase the and were the were a surface of receptors was the as T.J. M.H. J. Biol. Chem. 1996; 271: Scholar) with cells in were with and for at with in binding were then three with binding and for at to the were with binding and then with of and the of the was binding was with cells that were with of to mutant receptors was as a of binding to wild type receptor. 1 a of the wild type human VIP1 the amino acid residues that have been by mutagenesis in the We first histidine which highly conserved in class II G protein-coupled receptors. The mutant of the human VIP1 which the in constitutively PTH receptors E. H. 1995; Scholar), was transfected into and cAMP was The cAMP level was 3.5-fold the cAMP level of the wild type human VIP1 receptor or the vector This that the wild type receptor was not constitutively activated. constitutive of the H178R mutant was of the cell Chinese hamster cAMP level in cells transfected with the H178R mutant was that for the wild type and cells constitutive activation not to the of the cell the receptor cDNA. the cAMP response in cells transfected by H178R mutant and wild type receptors by cAMP were above level were for similar of VIP in cells transfected with the H178R receptor or the wild type and of VIP binding to cell that the H178R receptor mutant VIP with a similar dissociation constant as compared with the wild type receptor the of VIP binding sites was in cells transfected with the wild type receptor in cells transfected with the H178R receptor mutant This not the that the cAMP level in cells transfected with H178R related to a of the receptor as compared with cells transfected with the wild type receptor as the wild type receptor not constitutively by to this we transfected COS cells with of the H178R mutant or wild type receptor. the receptor was that cAMP of were transfected in COS cells the cAMP level in COS cells transfected with the wild type receptor was constant of the amount of transfected This constitutive of the wild type human VIP1 receptor the and wild type receptors, we that VIP cAMP with the amount of transfected the ligand binding that the amount of to transfected cell with the of transfected for the and wild type receptors and VIP-stimulated cAMP in COS cells wild type human VIP1 receptor or His178 mutants of the receptor. were for 30 at or with VIP The cAMP was as of three response of VIP in cAMP in COS cells the wild type human VIP1 receptor or the H178R receptor mutant were for 30 at in the of of VIP as The cAMP was as of three of wild type and human VIP receptors of into binding not binding not in a new and VIP-stimulated cAMP in COS cells transfected with of the the wild type human VIP1 receptor or the H178R receptor mutant were for 30 at or with the of three were to mutation of His178 into residues other arginine also resulted in constitutive activation of the human VIP1 receptor. We into a an or a was constitutively in cells mutants were to VIP-stimulated cAMP probably no longer VIP the of of mutants in transfected studies and binding were to human VIP1 receptors the sequence between and in the N-terminal extracellular domain of the human VIP1 receptor its with to VIP binding and VIP-stimulated cAMP that of the no the functional of this extracellular to studies with the wild type and receptors in nonpermeabilized transfected COS cells and also to cell surface of receptors by binding to nonpermeabilized transfected COS cells. of nonpermeabilized COS cells the wild type receptor with the and with an This delivery of the receptor at the cell surface as for the wild type receptor. COS cells that were with or COS cells the wild type receptor that were with the no we mutants including H178A, and that COS cells transfected with mutants also that mutants were expressed at the cell not we cell surface of receptors by binding to cells mutants and wild type receptor that mutation of His178 into or no in cell surface as compared with that of wild type into or in cell surface and of wild type that the of VIP binding and VIP-stimulated cAMP for the H178A, and mutants was not related to of at cell surface and was probably to a of binding with the constitutive and VIP binding of the H178R surface of human VIP1 receptors of into of wild in a new The that constitutive activation of the human VIP1 receptor by mutation of His178 into arginine not with into and and that such also abolished VIP binding that such constitutive activation might the integrity of the VIP binding this we constructed double mutants in which the mutation in the constitutive activation of the receptor was associated with point in the N-terminal extracellular domain of the which abolished VIP binding as (9Couvineau A. Gaudin P. Maoret J.J. Rouyer-Fessard C. Nicole P. Laburthe M. Biochem. Biophys. Res. Commun. 1995; 206: 246-252Google Scholar, P. Couvineau A. Laburthe M. 1996; Scholar). we a mutation an amino acid highly conserved in the class II G protein-coupled receptors, (9Couvineau A. Gaudin P. Maoret J.J. Rouyer-Fessard C. Nicole P. Laburthe M. Biochem. Biophys. Res. Commun. 1995; 206: 246-252Google Scholar). the H178R/D68A mutant no longer VIP the mutant the of cAMP by VIP that this double mutant no longer constitutively expressed in COS cells. was that the H178R/D68A mutant the mutant exhibited a cell surface similar to that of the wild type receptor as by and binding we an amino acid that was not conserved in the class II G protein-coupled receptors but the mutation of which abolished VIP binding E36A P. Couvineau A. Laburthe M. 1996; Scholar). the mutant the H178R/E36A mutant no longer VIP and not the of cAMP by VIP The double mutant was not constitutively expressed in COS cells was that the H178R/E36A the E36A mutant exhibited a cell surface similar to that of the wild type receptor as by and binding a we double mutant in which H178R was associated with a point mutation in the N-terminal extracellular which was not to VIP binding P. Couvineau A. Laburthe M. 1996; Scholar). the the mutant VIP with a dissociation constant similar to that of the wild type receptor This mutant also VIP-stimulated cAMP and exhibited cell surface similar to that of wild type receptor in nonpermeabilized transfected cells as by and binding the double mutant constitutive activation in COS cells The of or constitutive activation of G protein-coupled receptors has emerged mutagenesis of the receptor S. S. M. Acad. Sci. S. A. Scholar). was documented by the discovery of in J. L. Van J. M. J. G. Endocrinol. 1994; Scholar, A.M. 1995; Scholar) as well as S. P. Trends Sci. 1993; Scholar) in G protein-coupled receptors. the discovery of a constitutively mutant of the peptide receptor in E. H. 1995; Scholar), this the first to constitutive activation of a of the class II family of G protein-coupled receptors, the human VIP1 receptor. This that of histidine 178 by arginine in the human VIP1 receptor in constitutive activation of the receptor with respect to cAMP which its M. P. Couvineau A. Amiranoff B. 1993; Scholar). the wild type VIP receptor to in the of mutation of histidine 178 into arginine in constitutive activation of the into other residues such as and not This that the by arginine a change that by and probably not related to the of This that for the in which the amino acid at a constitutive that this to the G of the receptor in the in the wild type receptor S. J. J. Biol. Chem. Scholar). to the human VIP1 that the histidine to arginine not as in receptors S. J. J. Biol. Chem. Scholar) or receptors E. H. J. Biol. Chem. Scholar). this that the mutation of the histidine in the receptor in was also into arginine E. H. 1995; Scholar). The crucial of histidine 178 in the human VIP1 receptor by the that other arginine resulted in the of VIP binding and of cAMP the of an important structural change in the histidine to arginine not change the dissociation constant of the the of VIP in cAMP production. This with the since receptors that constitutively demonstrate a for the a of the of G protein-coupled receptors S. J. J. Biol. Chem. Scholar). to the was for constitutively receptors P. S. J. Biol. Chem. 1993; Scholar) or receptors H. D. J. 1995; Scholar). such an increase in the of constitutively receptors for was not for several other receptors such as the receptor P. Van J. J. L. H. E. G. N. J. 1995; Scholar) or the hormone receptor A. L. S. J.J. 1993; Scholar). A that constitutive activation of the II receptor by mutation in the third transmembrane domain not the and for B. C. J. J. Biol. Chem. Scholar). This that the of constitutive activation not between receptors and the class II family to which VIP receptors but also the class family of receptors for amines, peptides, or glycoprotein activation by of histidine 178 by arginine in the human VIP1 receptor activation by the natural VIP in the H178R mutant receptor or the wild type receptor. the of double mutants a between the activation by VIP and the by mutation of histidine 178 into the H178R mutation at the of the first loop and transmembrane domain was associated with mutation of in the N-terminal extracellular which VIP binding and VIP-stimulated cAMP (9Couvineau A. Gaudin P. Maoret J.J. Rouyer-Fessard C. Nicole P. Laburthe M. Biochem. Biophys. Res. Commun. 1995; 206: 246-252Google Scholar), the double mutant was no more constitutively and has the of the highly conserved in the class II family of receptors (3Laburthe M. Couvineau A. Gaudin P. Maoret J.J. Rouyer-Fessard C. Nicole P Ann. N. Y. Acad. Sci. 1996; 805: 94-109Google Scholar), that its mutation the overall structure of the receptor by the structure of the N-terminal extracellular domain. We have the N-terminal extracellular domain that not conserved in the class II family of receptors but mutation VIP binding and VIP-stimulated cAMP P. Couvineau A. Laburthe M. 1996; Scholar). the double mutant H178R/E36A was no longer constitutively and the as the mutant that the integrity of the VIP binding at the N-terminal extracellular domain maintained for constitutive activation by the H178R This was by a control double mutant a in the N-terminal extracellular domain mutation was not to the of the receptor P. Couvineau A. Laburthe M. 1996; Scholar). The double mutant constitutive that the H178R mutation VIP to the wild type receptor and activation of cAMP production. were of constitutive activation of other receptors A. S. J. Recept. Signal Transduct. Res. Scholar) such as receptors L. M. M. S.R. J. Biol. Chem. 1996; 271: Scholar) or receptors H. S. J. Biol. Chem. 1993; Scholar). that of constructing double mutants new that the change constitutive activation in a receptor mutant requires the functional integrity of the ligand binding This double mutation was for the VIP the binding in the N-terminal extracellular domain well the of the mutation constitutive the of such a double mutation has not been natural or in constitutive activation of G protein-coupled receptors have been in the third probably this loop in G activation by the receptor M. J. Recept. Signal Transduct. Res. 1995; 15: 131-160Google Scholar). have been also for several receptors in other domains including transmembrane and extracellular M. J. Recept. Signal Transduct. Res. 1995; 15: 131-160Google Scholar). in the N-terminal extracellular domain of the receptor L. M. M. S.R. J. Biol. Chem. 1996; 271: Scholar) or of a of this domain in the receptor H. S. Biochem. Biophys. Res. Commun. 1995; 211: Scholar) also transmembrane constitutively at the of the first loop and transmembrane domain have been for the VIP1 receptor and the receptor E. H. 1995; Scholar). such related to a of the class II family of G protein-coupled receptors with respect to to Gs proteins and of transmembrane that the third loop of members of class II family of receptors such as the glucagon-like peptide 1 receptor T.J. Biochem. Biophys. Res. Commun. 1996; Scholar) and the receptor Y. S. D.M. J. Biol. Chem. 1996; 271: Scholar) for to the cAMP as has been for other G protein-coupled receptors M. J. Recept. Signal Transduct. Res. 1995; 15: 131-160Google Scholar). about the in the of VIP1 receptors with Gs histidine 178 in the human VIP1 receptor strictly conserved in members of the class II family of receptors, of functional in G protein-coupled receptors. mutation of the histidine in other peptide receptor of this family in activation has been for the PTH receptor E. H. 1995; Scholar). this that two members of this family receptors having an extraordinary long N-terminal extracellular domain with the putative EGF module-containing, mucin-like hormone receptor EMR1 (5Baud V. Chissoe S.L. Viegas-Pequignot E. Diriong S. N'Guyen V.C. Roe B.A. Lipinski M. Genomics. 1995; 6: 334-344Google Scholar) and the leukocyte activation antigen CD97 (6Hamman J. Eichler W. Hamman D. Kersten H.M.J. Poddhige P.J. Hoovers J.M.N. Hartmann E. Strauss M. Van Vlier R.A.W. J. Immunol. 1995; 155: 1942-1950Google Scholar). the not mutation of the histidine in two receptors in with adenylyl this the first of a constitutively receptor the class II G protein-coupled receptor Our the of the N-terminal extracellular binding domain in the of constitutive activation of the VIP1 receptor. the extracellular ligand binding domain also important in the of constitutive activation of other class II G protein-coupled receptors to
39
Andrew Shenker, Louisa Laue, Shinji Kosugi et al. · Nature · 1993 · 756 citations · Full text
Medicine, Endocrinology, Genetics +14
Michael A. Kjelsberg, Susanna Cotecchia, Jerzy Ostrowski et al. · Journal of Biological Chemistry · 1992 · 599 citations · Full text